"Inhaled Nitric Oxide as an Adjunctive Treatment for Cerebral Malaria in Children: A Phase II Randomized Open-Label Clinical Trial" by Mwanga-Amumpaire et al (Summer 2015 2(3):doi:10.1093/ofid/ofv111) neglected to include author Kenneth D. Block\'s affiliation with Harvard Medical School (\#11), neglected to use subscript numbers for nitrogen in Figure [2](#OFV132F2){ref-type="fig"} and Figure [3](#OFV132F3){ref-type="fig"} captions (N~2~), and also inverted Figure 2 and Figure 3. The corrected figures and captions appear below. Figure 2.(A) Delivered dose of nitric oxide (NO) over 120 hours (mg/kg per hour); (B) blood methemoglobin (percentage of methemoglobin \[metHb %\]) in patients treated with nitrogen (N~2~) and NO; (C) Plasma nitrate (μM) levels; and (D) plasma nitrite (μM) levels in patients treated with N~2~ or NO. \**P* \< .001 and \*\**P* \< .05, NO versus N~2~. All data mean ± standard deviation. Figure 3.(A) Kaplan-Meier curves comparing survival in pediatric patients with cerebral malaria (CM) treated with nitrogen (N~2~) or nitric oxide (NO). *P* = not significant (NS). (B) Kaplan-Meier curves for resolution of coma in pediatric patients with CM, N~2~ vs NO; resolution of coma is defined as Blantyre coma score ≥ 3 or Glasgow coma score of ≥7; (N~2~ N = 39, NO N = 41). *P* = NS. Abbreviations: INO, inhaled NO; metHb%, percentage of methemoglobin.
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